Screener
BridgeBio Pharma BBIO Reportable Segment — Income (Loss) from Equity Method Investments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Interest expense | (12,942) | (18,121) |
| Noncash interest expense on deferred royalty obligations (1) | (39,873) | (24,020) |
| Loss on extinguishment of debt | — | (21,155) |
| Net loss from equity method investments | (18,283) | (15,556) |
| Other income, net | 4,253 | 8,231 |
| Total other expense, net | (60,599) | (65,236) |
| Net loss | (166,555) | (169,608) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 2,512 | 2,186 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's reportable segment — income (loss) from equity method investments?
- BridgeBio Pharma (BBIO) reported reportable segment — income (loss) from equity method investments of -$18.28M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — income (loss) from equity method investments changed year-over-year?
- BridgeBio Pharma's reportable segment — income (loss) from equity method investments decreased by 17.5% year-over-year, from -$15.56M to -$18.28M.
- What does reportable segment — income (loss) from equity method investments mean?
- This represents the company's share of the net earnings or losses of entities in which it holds a significant influence but not a controlling interest. It reflects the performance of strategic partnerships, joint ventures, or minority stakes in other biotech or pharmaceutical entities. This line item captures the economic impact of collaborative research or development efforts managed through equity-accounted vehicles.
Ask your AI about BridgeBio Pharma's reportable segment — income (loss) from equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude